CRM-система как инструмент повышения эффективности деятельности компании

Объектом исследования является ООО "СМЕТ". Предметом исследования является управление взаимоотношениями с клиентами. Цель работы – рассмотрение CRM-систем как инструмент повышения эффективности бизнеса. Актуальность работы: в новых условиях компаниям продавать свои товары и услуги и удерживать клиентов стало намного сложнее. Клиенты стали тщательнее "считать деньги", торговаться и экономить. Покупательский спрос смещается в сторону более дешевых предложений, клиенты отказываются от всего дополнительного и необязательного, сопутствующих товаров. Усиливается конкуренция на рынках внутри страны.The object of this study is LLC "ESTIMATES". The subject of this study is customer relationship management. Purpose - consideration of CRM-systems as a tool to improve business performance. Relevance of the work: under the new conditions the companies sell their products and services and hold the customer has become much more difficult. Customers have become more thoroughly "counting money" to trade and save. Consumer demand shifts toward lower-cost offerings, customers abandon all the extra and optional, related products. There is a growing competition in the domestic markets and with foreign companies

The U.S. Law of Client Confidentiality: Framework for an International Perspective

In this Article, I will consider two general areas of the U.S. law of confidentiality. In Part I, I will reflect briefly upon what I call “the U.S. culture of lawyer-client confidentiality.” I say “culture” rather than “cult,” and one must guard against temptations to confuse those concepts. Those reflections will serve as background—by way of both match and contrast—to my sketch of the U.S. law of confidentiality in Part II

Информационная система учета, подбора и анализа индивидуальных программ реабилитации для людей с ограниченными возможностями

Объектом исследования является процесс подбора и анализа индивидуальных программ реабилитации для людей с ограниченными возможностями. Цель работы – разработка информационной системы для учета, подбора и анализа индивидуальных программ реабилитации для людей с ограниченными возможностями. В процессе исследования проводился теоретический анализ, обзор аналогов, проектирование и разработка информационной системы. В результате разработана информационная система, реализующая функции: учет организаций, занимающихся реабилитацией; учет заявлений и направлений на реабилитацию; подбор индивидуальных программ реабилитации; учет итогов проведенных реабилитаций и анализ проведенных реабилитаций.The object of research is the process of selection and analysis of individual rehabilitation programs for people with disabilities. The purpose of work is development of an information system for recording, selection and analysis of individual rehabilitation programs for people with disabilities. During research theoretical analysis, review of analogues, design and development of the information system were carried out. As a result, the information system that implements the following functions was developed: accounting organizations dealing with rehabilitation; account of applications statements and medical referral for rehabilitation; selection of individual rehabilitation programs; accounting of results of the recovery and analysis of the process of rehabilitation

Atrial arrhythmogenesis in wild-type and Scn5a+/Δ murine hearts modelling LQT3 syndrome

Long QT(3) (LQT3) syndrome is associated with abnormal repolarisation kinetics, prolonged action potential durations (APD) and QT intervals and may lead to life-threatening ventricular arrhythmias. However, there have been few physiological studies of its effects on atrial electrophysiology. Programmed electrical stimulation and burst pacing induced atrial arrhythmic episodes in 16 out of 16 (16/16) wild-type (WT) and 7/16 genetically modified Scn5a+/Δ (KPQ) Langendorff-perfused murine hearts modelling LQT3 (P < 0.001 for both), and in 14/16 WT and 1/16 KPQ hearts (P < 0.001 for both; Fisher’s exact test), respectively. The arrhythmogenic WT hearts had significantly larger positive critical intervals (CI), given by the difference between atrial effective refractory periods (AERPs) and action potential durations at 90% recovery (APD90), compared to KPQ hearts (8.1 and 3.2 ms, respectively, P < 0.001). Flecainide prevented atrial arrhythmias in all arrhythmogenic WT (P < 0.001) and KPQ hearts (P < 0.05). It prolonged the AERP to a larger extent than it did the APD90 in both WT and KPQ groups, giving negative CIs. Quinidine similarly exerted anti-arrhythmic effects, prolonged AERP over corresponding APD90 in both WT and KPQ groups. These findings, thus, demonstrate, for the first time, inhibitory effects of the KPQ mutation on atrial arrhythmogenesis and its modification by flecainide and quinidine. They attribute these findings to differences in the CI between WT and mutant hearts, in the presence or absence of these drugs. Thus, prolongation of APD90 over AERP gave positive CI values and increased atrial arrhythmogenicity whereas lengthening of AERP over APD90 reduced such CI values and produced the opposite effect

Experiences from treating seven adult 5q spinal muscular atrophy patients with Nusinersen

Background: The antisense oligonucleotide Nusinersen recently became the first approved drug against spinal muscular atrophy (SMA). It was approved for all ages, albeit the clinical trials were conducted exclusively on children. Hence, clinical data on adults being treated with Nusinersen is scarce. In this case series, we report on drug application, organizational demands, and preliminary effects during the first 10 months of treatment with Nusinersen in seven adult patients. Methods: All patients received intrathecal injections with Nusinersen. In cases with severe spinal deformities, we performed computed tomography (CT)-guided applications. We conducted a total of 40 administrations of Nusinersen. We evaluated the patients with motor, pulmonary, and laboratory assessments, and tracked patient-reported outcome. Results: Intrathecal administration of Nusinersen was successful in most patients, even though access to the lumbar intrathecal space in adults with SMA is often challenging. No severe adverse events occurred. Six of the seven patients reported stabilization of motor function or reduction in symptom severity. The changes in the assessed scores did not reach a significant level within this short time period. Conclusions: Treating adult SMA patients with Nusinersen is feasible and most patients consider it beneficial. It demands a complex organizational and interdisciplinary effort. Due to the slowly decreasing motor functions in adult SMA patients, long observation phases for this recently approved treatment are needed to allow conclusions about effectiveness of Nusinersen in adults

Corruption in the Middle East and the Limits of Conventional Approaches

Die Unzufriedenheit mit der verbreiteten Korruption war 2011/2012 eine wesentliche Ursache für die arabischen Unruhen und weitere Aufstände weltweit. Der Fall Jordanien zeigt allerdings, dass konventionelle Ansätze zur Bekämpfung von Korruption nicht ausreichen. Eine angemessene Strategie gegen Korruption muss diese als ein Problem der Verteilungsgerechtigkeit und nicht des Strafrechts verstehen. Wie in allen anderen arabischen Staaten ist die Unzufriedenheit in der Bevölkerung über die offensichtliche Korruption auch in Jordanien beträchtlich. Allerdings wird im Allgemeinen nicht über Fälle von Bestechung und Erpressung geklagt, die weniger häufig vorkommen, sondern über lokale Praktiken politischer Patronage und Begünstigung, die unter dem Begriff "Wasta" zusammengefasst werden. "Wasta" wurde bislang als Form der Korruption und strafrechtliches Problem angesehen, weshalb Versuche zur Eindämmung überwiegend ineffizient blieben: "Wasta"-Praktiken werden in der Regel nicht mit Rechtsverstößen verbunden, sondern bewegen sich innerhalb formal legaler Verfahren. Konventionelle Ansätze zur Bekämpfung von Korruption, die sich an rechtsstaatlichen Grundsätzen und Transparenz orientieren, sind deshalb nicht zielführend. Demokratisierung allein ist ebenfalls ungeeignet, das Problem „Wasta” zu lösen. In der parlamentarischen Praxis macht "Wasta" den Großteil der Aktivitäten aller Parlamentsmitglieder aus. Diese werden deshalb als persönliche Dienstleister für ihre Wahlbezirke und nicht als Mitglieder einer gesetzgebenden Körperschaft wahrgenommen. Gleichzeitig hält die Bevölkerung das Parlament für eine zutiefst korrupte Institution. "Wasta" wird problematisch, wenn diese Praxis zu einem ungleichen Zugang der Bürger zu öffentlichen Ressourcen führt. Statt sich nur auf politische und administrative Reformen zu konzentrieren, muss der Fokus der Bekämpfung auf den (Wieder-)Aufbau wohlfahrtsstaatlicher Strukturen gelegt werden, zu denen alle Bürger gleichermaßen Zugang haben

Оценка конкурентоспособности организации

Цель работы: обозначить пути повышения конкурентоспособности предприятия-производителя электротехнической продукции ООО «СИБАР ГРУПП» В процессе исследования проводились: анализ финансово-хозяйственной деятельности, анализ ассортимента предприятия, выделены основные финансовые показатели деятельности предприятия, проведен анализ конкурентной среды предприятия В результате исследования выявлены слабые места предприятия, рекомендованы меры по повышению конкурентоспособности предприятия на рынке электротехнического оборудования Экономическая эффективность/значимость работы: исполнение рекомендаций для повышения конкурентоспособности В будущем планируется: дальнейшее повышение конкурентоспособности.A research object is LTD "SIBAR GROUP" plant of electrical engineering equipment. Aim of work : to designate the ways of increase of competitiveness of enterprise on the example of enterprise LTD "SIBAR GROUP". In the process of research conducted: analysis of financially-economic activity, analysis of assortment of enterprise, basic financial performance of enterprise indicators are distinguished, the analysis of competition environment of enterprise is conducted. As a result of research the weak points of enterprise are educed, measures are recommended on their strengthening. Basic structural, technological and operating descriptions. Economic efficiency/ is meaningfulness of work : execution of recommendations for the increase of competitiveness

Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe)

Background Non-vitamin K antagonist (VKA) oral anticoagulants (NOACs) have substantially improved anticoagulation therapy for prevention of stroke and systemic embolism in patients with atrial fibrillation (AF). The available routine care data have demonstrated the safety of different NOACs; however, such data for edoxaban are scarce. Here, we report baseline characteristics of 13,638 edoxaban-treated patients with AF enrolled between November 2016 and February 2018. Methods ETNA-AF-Europe is a multinational, multi-centre, post-authorisation, observational study conducted in 825 sites in 10 European countries. Patients will be followed up for four years. Results Overall, 13,980 patients were enrolled of which 342 patients were excluded from the analysis. Mean patient age was 73.6 years with an average creatinine clearance of 69.4 mL/min. 56.6% were male. The calculated CHA2DS2-VASc and HAS-BLED mean scores were 3.1 and 2.6, respectively. Overall, 3.3, 14.6 and 82.0% of patients had low (CHA2DS2-VASc = 0), intermediate (CHA2DS2-VASc = 1) and high (CHA2DS2-VASc≥2) risks of stroke, respectively. High-risk patients (those with prior stroke, prior major bleeding, prior intracranial bleed or CHA2DS2-VASc ≥4) comprised 38.4% of the overall population. For 75.1% of patients edoxaban was their first anticoagulant prescription, whilst 16.9% switched from a VKA and 8.0% from another NOAC. A total of 23.4% of patients in ETNA-AF-Europe received the reduced dose of edoxaban 30 mg. Overall, 83.8% of patients received an edoxaban dose in line with the criteria outlined in the label. Conclusion Edoxaban was predominantly initiated in older, often anticoagulation-naïve, unselected European patients with AF, with a good overall adherence to the approved label. Trial registration NCT02944019; Date of registration: October 24, 2016